Seminar: Dr. Christoph Schröder & Dr. Ronny Schmidt

Sciomics: antibody meets Microarray

Date:
3 November 2014 15:00 hrs. - 16:00 hrs.
Location:
Figdor Lecture Theatre, 8th floor RIMLS Building, Geert Grooteplein 26-28, route 289
Title:
Sciomics: antibody meets Microarray
Speaker(s):

Dr. Christoph Schröder & Dr. Ronny Schmidt, Sciomics GmbH, German Cancer Research Center, Heidelberg, Germany

 

Host(s):

Ghaith Bakdash, PhD, Dept. of tumor Immunology, RIMLS

 

03-11-2014 15:00:0003-11-2014 16:00:00Europe/AmsterdamSciomics: antibody meets Microarray  Figdor Lecture Theatre, 8th floor RIMLS Building, Geert Grooteplein 26-28, route 289Rimlsrimls@radboudumc.nl

Remarks / more information:

Schroder , ChristophSchmidt , RonnySciomics is a German Cancer Research Center (DKFZ) spin-off company and located in Heidelberg, Germany, with a strong scientific focus. In the past ten years, we have contributed significantly to the scientific development of our complex antibody microarray platform. With antibody microarrays target proteins can be analyzed in a highly-parallelized fashion with minute amounts of sample rendering this technique very reliable, time and cost-efficient. Based on complex antibody arrays and in close cooperation with academic partners, we have indentified various biomarker signatures e.g. for a prognosis in bladder cancer, a diagnosis of pancreatic cancer and an early diagnosis of acute kidney injury for which Sciomics is now entering into the development of in-vitro diagnostics. Next to our internal R&D activities, Sciomics offers a full analysis service on various microarray formats closely working with our partners and clients in the fields of biomarker discovery or protein expression analysis. Furthermore, we are specialized in antibody quality control and custom microarray production.

 

Key Publications:

  • Dual-color proteomic profiling of complex samples with a microarray of 810 cancer-related antibodies. Mol. Cell Proteomics 9:1271-80, 2010.
  • Prediction of recurrence of non muscle-invasive bladder cancer by means of a protein signature identified by antibody microarray analyses. Proteomics, 14: 1333-42, 2014
  • Plasma protein analysis of patients with different B-cell lymphomas using high-content antibody microarrays. Proteomics Clin. Appl. 7: 802-812, 2013.

 



<< back to all events